C V Therapeutics' angina drug filings accepted (PharmaBiz)
Biopharmaceutical company, CV Therapeutics, Inc. announced that the US Food and Drug Administration (FDA) has accepted its supplemental new drug application (sNDA) as well as its new drug application (NDA) for chronic angina drug Ranexa.

FDA Accepts Ranexa(R) sNDA and NDA for Filing (The San Francisco Examiner)
PALO ALTO, Calif. ( Map ) - PALO ALTO , Calif., Nov 19 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX ) announced today that the U.S. Food and Drug Administration (FDA) has notified the Company that its supplemental new drug application (sNDA) and new drug application (NDA) for Ranexa(R) (ranolazine extended- release tablets) have both been accepted for filing.